Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation
Publisher
Aptose Biosciences
Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.
Canonical metadata stays public, while full text remains on the original site.